- AI
- Molecular Imaging
- CT
- X-Ray
- Ultrasound
- MRI
- Facility Management
- Mammography
Syncor sees jump in operating income
Radiopharmaceutical firm Syncor International had reason to celebrate this month when it posted a dramatic increase in operating income for third quarter 1999 (end-September). The Woodland Hills, CA, firm’s operating income climbed 48% during the
Radiopharmaceutical firm Syncor International had reason to celebrate this month when it posted a dramatic increase in operating income for third quarter 1999 (end-September). The Woodland Hills, CA, firms operating income climbed 48% during the quarter, to $8.3 million from $5.6 million the year before. Net sales increased by 15% to $131.5 million, up from $114 million in 1998. The company reported net income of $3.2 million, compared with $2.7 million for the same period the previous year. Included in Syncors results was a nonoperating write-down of $1.8 million linked to the companys 1997 investment in Perimunne, a biotechnology company.
The company attributed its strong performance to increased market demand for pharmacy services, as well as sales revenue and acquisitions in its medical imaging business. For the quarter, Syncors radiopharmacy gross margin increased by $4.3 million to comprise 27% of the companys sales. Its medical imaging business, which operates under a subsidiary, Comprehensive Medical Imaging, posted sales of $15.7 million for the quarter, compared to $11 million in 1998. Comprehensive Medical Imaging acquired four imaging centers in Southern and Central California during the quarter.
New AI-Powered Ultrasound Devices May Enhance Efficiency in Women's Imaging
April 19th 2024One of the features on the new Voluson Signature 20 and 18 ultrasound devices reportedly uses automated AI tools to facilitate a 40 percent reduction in the time it takes to perform second trimester exams.
FDA Approves Fluorescence Imaging System for Detecting Residual Breast Cancer
April 18th 2024The combination of the optical imaging agent Lumisight and the fluorescence imaging device Lumicell Direct Visualization System, collectively known as LumiSystem, reportedly offers 84 percent accuracy with real-time detection of residual breast cancer after lumpectomy procedures.
Study of Ofatumumab for Multiple Sclerosis Shows 'Profoundly Suppressed MRI Lesion Activity'
April 17th 2024The use of continuous ofatumumab in patients within three years of a relapsing multiple sclerosis diagnosis led to substantial reductions in associated lesions on brain MRI scans, according to research recently presented at the American Academy of Neurology (AAN) conference.
